| Open Document File Size: 739,10 KBShare Result on Facebook
City Cambridge / / Company Astex Pharmaceuticals Inc. / INTRODUCTION 1Astex Pharmaceuticals / / Country United Kingdom / Belgium / / Facility Women’s Hospital / University Hospitals / Laboratory of Experimental Oncology / Catholic University of Leuven / / IndustryTerm Cancer Therapeutics / / MedicalCondition tumor / gastrointestinal stromal tumors / necrosis / tumors / resistant gastrointestinal stromal tumor / / Organization Women’s Hospital / / Position General / / Technology Pharmacodynamics / /
SocialTag |
The HSP90 inhibitor, AT13387, demonstrates potent anti-tumor activity in both imatinib-sensitive and -resistant gastrointestinal stromal tumor models No A217 Tomoko Smyth1, Thomas Van Looy2, Jayne Curry1, Ana Rodriguez-